Peptron says Lilly technology evaluation ended without a main contract
In short
Peptron said on Oct 7 that the technology evaluation of its long-acting drug delivery platform SmartDepot with Eli Lilly has ended. The company said the end of the evaluation does not mean commercialization cooperation has ended and that follow-up talks will continue, while another outlet reported follow-up cooperation is undecided. Korea Economic Daily reported the shares fell 28% in aftermarket trading.
Read the full story 1 min read
Peptron said on Oct 7 that the technology evaluation of its long-acting drug delivery platform SmartDepot with Eli Lilly has ended, according to Chosun Ilbo and Newsis. Korea Economic Daily's headline said the evaluation ended without a main contract with Lilly. [ 1 , 2 , 3 ]
Chosun Ilbo reported that the company said in a shareholder notice that the end of the evaluation does not mean its commercialization cooperation with Lilly has ended, and that it plans to continue follow-up talks based on the results of joint research. Newsis reported instead that follow-up cooperation is undecided. Korea Economic Daily reported that Peptron shares fell 28% in aftermarket trading, a figure no other document mentions. The documents did not give the terms of the evaluation, its financial details or a timetable for any further talks. [ 1 , 2 , 3 ]
Why it matters
The outcome of the Lilly evaluation matters for Peptron's pipeline of long-acting obesity and diabetes drug delivery technology and for how investors price the company. The documents show the two sides have not announced a commercial contract, leaving the next step open. All three documents come from domestic business outlets, and none gave financial terms or a timetable.
Key facts
- Peptron said its technology evaluation with Eli Lilly for the long-acting drug delivery platform SmartDepot has ended. [ 1 , 2 , 3 ]
- Korea Economic Daily reported the evaluation ended without a main contract with Lilly. [ 1 ]
- Peptron said the end of the evaluation does not mean its commercialization cooperation with Lilly has ended, and that it plans follow-up talks based on joint research results, Chosun Ilbo reported. [ 2 ]
- Newsis reported that follow-up cooperation with Lilly is undecided. [ 3 ]
- Korea Economic Daily reported Peptron shares fell 28% in aftermarket trading. [ 1 ]
- Peptron said the notice was given to shareholders on Oct 7. [ 2 ]
Confirmed by several sources
Still unclear
- Whether Peptron and Eli Lilly will sign a main contract or continue cooperation. Chosun Ilbo reports the company saying follow-up talks will continue, while Newsis reports follow-up cooperation is undecided and Korea Economic Daily's headline says the evaluation ended without a main contract.
- The reported 28% fall in Peptron shares in aftermarket trading. Stated only by Korea Economic Daily; no other document mentions the share move or gives a price.
- Financial terms, scope of the evaluation and any timetable for further talks. None of the documents provides these details.
What local media are saying
Timeline, local time
- Korea Economic Daily reports that Peptron's technology evaluation ended without a main contract with Lilly and that the shares fell 28% in aftermarket trading. [ 1 ]
- Chosun Ilbo reports Peptron's shareholder notice saying the SmartDepot technology evaluation with Eli Lilly has ended and that follow-up discussions will continue. [ 2 ]
- Newsis reports that the technology evaluation period with Lilly has ended and that follow-up cooperation is undecided. [ 3 ]